Servier Bio-Innovation
Clinical trials sponsored by Servier Bio-Innovation, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New immunotherapy cocktails aim to shrink tough lung tumors Results expected Apr 2027 (estimated)
- New drug combo targets Hard-to-Treat cancers with MTAP deletion Results expected May 2027 (estimated)
- New antibody combo takes on Hard-to-Treat stomach cancers Results expected Aug 2027 (estimated)
-
New drug combo targets Hard-to-Treat cancers with MTAP deletion
Disease control OngoingThis early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New immunotherapy cocktails aim to shrink tough lung tumors
Disease control OngoingThis study tests three different immunotherapy drug combinations in people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. The goal is to see if adding another immune-boosting drug to the standard anti-PD1 therapy can better co…
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody combo takes on Hard-to-Treat stomach cancers
Disease control OngoingThis study tests a new antibody drug, S095029, combined with the immunotherapy pembrolizumab in people with advanced stomach or gastro-esophageal junction cancer that has a specific genetic feature (MSI-H/dMMR). The trial aims to see if the combination is safe and can shrink tumo…
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC